#Tevogen Bio

[otiskeene]

Tevogen Bio Introduces Tevogen.ai To Enhance Patient Accessibility And Accelerate Innovation Leveraging Artificial Intelligence

The pharmaceutical business is about to undergo a revolution in several areas, including medication research, development, manufacturing, distribution, and patient access. Tevogen Bio Inc. has launched Tevogen.ai, a ground-breaking effort that aims to leverage artificial intelligence (AI) to transform these areas. With a focus on the ethical development and commercialization of AI-driven technologies that improve health outcomes and expedite operations, this program brings together a team of professionals including research scientists, physicians, data scientists, and AI/machine learning engineers.

Tevogen Bio's CEO, Ryan Saadi, MD, MPH, stressed that the introduction of Tevogen.ai marks a substantial advancement in medical technology. Tevogen Bio hopes to significantly improve healthcare by fusing their biotechnology know-how with AI's capabilities. They think that the future of healthcare will be more widely available individualized immunotherapies, and that creative economic strategies will be essential to advancing medical innovation in the post-pandemic age.

A group of eminent scientists and seasoned business executives with backgrounds in medication development and international product launches run Tevogen Bio. Their mission is to drive innovation in the medical profession by providing accessible, individualized immunotherapies and innovative commercial models.

Read More - https://bit.ly/48LUxV8

[fmarkets]

$K #SP500 #NASDAQ #SPX $OMG-USD

The markets are in green on Wednesday, August 14, 2024, with numerous stocks making headlines. Here are today's key updates: Western Digital Shows Resilience Amid Market Volatility In a climate of fluctuating stock performance and competitive innovation, Western Digital Corp. (NASDAQ: WDC) finds itself at a crossroads, showcasing both resilience and vulnerability in the face of market challenges. Recent Stock PerformanceOn August 6, 2024, shares of Western Digital inched up by 0.68%, closing at $57.38. However, this modest gain did little to bolster the company's overall market performance, which underperformed relative to the broader SandP 500, which had risen by 1.04%. This trend seemed to reflect a broader struggle as, just a day earlier, the company had endured its third consecutive day of losses, highlighting a degree of volatility that investors cannot ignore. Tevogen Bios Amplifies Innovation with Prof. Sten Vermund?s Appointment In a groundbreaking announcement, Tevogen Bio Holdings Inc acknowledges and congratulates Professor Sten Vermund, MD, PhD, for his recent appointment as the esteemed dean of the University of South Florida (USF) Health College of Public Health. This remarkable milestone not only propels Professor Vermund?s distinguished career but also marks a new era of innovation and advancement for Tevogen Bio and the broader field of public health. Professor Vermund?s extensive expertise and contributions to the medical and public health realms have garnered him immense recognition and respect in the industry. This recent appointment further solidifies his influential role in shaping the future of healthcare. GlobalTech Corporation Establishes Advanced AI Center in Pakistan In an exciting development for the tech industry, GlobalTech Corporation has announced the establishment of its highly advanced Big Data and artificial intelligence (AI) Center of Excellence in Pakistan. Scheduled to be completed by the first quarter of 2025, the center will be housed within the premises of WorldCall Telecom Limited, a subsidiary of GlobalTech. By choosing Pakistan as the location for this significant venture, GlobalTech aims to leverage the country?s immense talent pool and foster a culture of innovation in the region. ADMA Biologics Announces Partial Paydown of Revolving Credit Fa https://csimarket.com/news/news_markets.php?date=2024-08-14T16294&utm_source=dlvr.it&utm_medium=tumblr

[jeroldloree]

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio ... - ForexTV

http://dlvr.it/T1tllG

[melbournenewsvine]

Warren-based biotechnology company Tevogen Bio CEO nominated for 2023 Nobel Peace Prize

Warren-based Tevogen Bio and its founder and CEO, Dr. Ryan Saadi, have been nominated for the 2023 Nobel Peace Prize by Curtis Patton, professor emeritus, Yale School of Public Health, Yale University. Patton, who was one of Saadi’s professors at Yale, said he nominated Tevogen and Saadi  because of the truly amazing work the company does, and for Saadi’s brilliance and qualities as a human being. An accomplished graduate of Harvard Business School Executive Education Program, Yale School of Medicine and Dhaka Medical College, Saadi has dedicated his life to various health care matters within both the private sector as well as public. Ryan Saadi. (Photos courtesy Tevogen) “We are honored and humbled by the news that Tevogen Bio has been nominated for the Nobel Peace Prize,” Saadi said. “The distinction reinforces our guiding principle that sustainable business success can be an unattainable concept unless the success contributes to societal prosperity, health and well-being of all people and, ultimately, a peaceful existence of all humans.” Each year, thousands of members of academies, university professors, scientists, previous Nobel Prize laureates and members of parliamentary assemblies and others are asked to submit candidates for the Nobel Prizes for the coming year. The nomination processes start in September each year. Curtis Patton. “Helping people to stay healthy, especially those who may have been at a distance from resources, is a good thing and important thing to do. And something most of us would want to do, but we can’t clean up the world,” Patton said. Tevogen is a late-stage clinical biotechnology company that specializes in the development of cell and gene therapies in oncology, neurology and virology.  It successfully completed the Proof-of-Concept clinical trial of its lead product candidate, TVGN 489, for elderly and/or high-risk ambulatory COVID-19 patients, in which no dose limiting toxicities or treatment-related adverse events were observed. “He is obviously a very, very brilliant young man. He is committed to the health of others and especially those who have been sort of omitted from opportunities to return to health,” Patton added. “He is also offering opportunities to stay away from dangerous infectious diseases, and, because of Tevogen’s work in developing vaccine products that will be supportive of people either in coming back to health or that will prevent them from having infectious diseases,  I’m sure you will agree that in general that sounds like a good thing to do and that his work and contributions fit with peace.” Patton said he also finds the work Tevogen does remarkable, as the company is committed to developing lifesaving innovations for diseases and cancers for which there is a very high unmet need. And Saadi is the main driver for the products that come out of Tevogen. “He is in every way a wonderful human being who is interested in the welfare of others and who has sacrificed his time and contributed his intelligence and drive to help people he may never know. I can’t think of anything more wonderfully peaceful,” Patton added. Under Saadi’s direction, Tevogen’s TVGN-489 recently received clearance to proceed from the U.S. Food and Drug Administration. The proprietary immunotherapy technology employs highly purified allogeneic cytotoxic T lymphocytes that are capable of recognizing specific targets encoded by SARS-CoV-2 and eliminating virus infected cells. The company is also exploring use of its proprietary technology to treat other viral infections, such as Hepatitis B, HPV, HIV and CTL-based therapeutics for solid and hematologic malignancies. Source link Originally published at Melbourne News Vine

[techsciresearch]

Curative Therapeutics Market to Grow with Technological Advancement During the Forecast Period | TechSci Research

Expanding healthcare industry is driving the growth in Global Curative Therapeutics Market in the forecast period, 2022-2026.

According to TechSci Research report, “Curative Therapeutics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2016-2026”, the global curative therapeutics market would potentially project an impressive growth in the forecast period, 2022-2026, with an impressive CAGR on account of increasing demand from the population suffering from chronic diseases. The rapidly growing instances of chronic diseases and their treatment is driving the growth of the global curative therapeutics market.

Extended research and innovative procedural launches of the technological advanced devices and equipment for the early diagnosis and effective therapeutic treatment also supports the growth of the global curative therapeutics market in the next five years. Government policies and strict regulations toward utilization of curative therapies since they are new and protocolled clinical trials are further aiding the growth of the global curative therapeutics market.

Gene therapy, biotechnological advances, and pharmaceutical innovations to cure diseases through aggressive treatment are substantiating the growth of the global curative therapeutics market in the forecast years. The recent outbreak of COVID-19 pandemic is also expected to play a vital role in the growth of the global curative therapeutics market in the forecast period, until 2026.

Multiple market players and research institutes expanded their production capabilities for vector production. For example, Tevogen Bio collaborated with BioCentriq to produce Tevogen’s investigational COVID-19 T-Cell Therapy which is under review for Food and Drug Administration (FDA) approval.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Curative therapeutics Market"

https://www.techsciresearch.com/report/curative-therapeutics-market/8012.html

The global curative therapeutics market is segmented on the basis of type, indication, end user, competitional landscape, and regional distribution. Based on type, the market is further fragmented into biology modifying drugs, gene therapies, and cell therapies. Cell therapies are anticipated to hold the largest revenue shares of the market and support the futuristic market growth on the account of their increasing demand. Cell therapies are actively involved in the cure for cancer.

The ongoing clinical trials and increasing pharmaceutical and healthcare product development based on cell therapy is increasing and thus supporting the growth of the sub segment as well as the growth of the global curative therapeutics market in the upcoming five years. Gene therapy is also anticipated to register significant growth in the next five years on account of increasing research and technological advancements.

Surging demand for the precision medicine, and genomic medicine is further aiding the growth of the gene therapy and thus drive the growth of the global curative therapeutics market in the future five years. Biology modifying drugs are expected to register fastest growing CAGR in the future on account of increasing research on pharmaceutical products. Although the procedure is quite risky, the adaptation and FDA approvals are expected to support the future growth of the segment and the global curative therapeutics market in the forecast period.

Based on indication, the market is segmented into cancer, musculoskeletal disorders, neurodegenerative diseases, rare diseases, hepatitis C, and others. Cancer in anticipated to register fastest growing CAGR due to rapidly increasing number of cases on a global scale. Moreover, hepatitis C cases are also multiplying and thus demand for the curative therapeutics has surged in the recent past years.

Neurodegenerative diseases are expected to register significant growth in the revenue shares in the future five years due to increasing research on neural disorders, related diseases, and brain diseases such as Alzheimer’s, Wilson’s.

Pfizer, Inc., GlaxoSmithKline plc., Sanofi S.A. (Genzyme-Voyager Therapeutics), bluebird bio, Inc., Novartis International AG, Spark Therapeutics, Inc., Kite Pharma Inc., Gilead Sciences, Inc., are among the major market players leading the growth of the global curative therapeutics market.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8012

Customers can also request for 10% free customization on this report.

“North America is anticipated to dominate the global market, which can be attributed to the rising financial and physical investment in the research and technological advancement. Advanced product launches and advancement in the therapies for the betterment of the population by the multiple market players is further driving the growth of the global curative therapeutics market in the upcoming five years. Government bodies like FDA for the approval of the therapies and pharmaceutical products along with the participation of the private organizations in clinical trials is further aiding the growth of the global curative therapeutics market. Ongoing alliances, and acquisitions in the US contributes towards futuristic market growth. New market players may focus on studying the consumer demand and extended research along with the smart product launches to aid brand establishment,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Curative Therapeutics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2016-2026 Segmented By Type (Biology Modifying Drugs, Gene Therapies, Cell Therapies), By Indication (Cancer, Musculoskeletal Disorders, Neurodegenerative Diseases, Rare Diseases, Hepatitis C, Others), By End User (Pharmaceutical Companies, Academic & Research Institutions, Others), By Region”, has evaluated the future growth potential of global curative therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global curative therapeutics market.

Browse Related Reports:

Global Cell & Gene Therapy Drug Delivery Devices Market By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) By Method (In Vitro v/s Ex Vivo) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/cell-and-gene-therapy-drug-delivery-devices-market/7364.html

Global Regenerative Medicine Market By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Others), By Application (Musculoskeletal Disorders, Wound Care, Others), By Material (Synthetic Material, Biologically Derived Material, Others), By Cell (Autologous, Allogenic), By Product (Biologic, Cell -based Medical Devices, Others), By Technique (Microfracture, Mosaicplasty), By Distribution Channel (Hospitals, Clinics, Others), By Region & Opportunities, 2025

https://www.techsciresearch.com/report/regenerative-medicine-market/4685.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techscimarketresearch]

Curative Therapeutics Market to Grow with Technological Advancement During the Forecast Period | TechSci Research

Expanding healthcare industry is driving the growth in Global Curative Therapeutics Market in the forecast period, 2022-2026.

According to TechSci Research report, “Curative Therapeutics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2016-2026”, the global curative therapeutics market would potentially project an impressive growth in the forecast period, 2022-2026, with an impressive CAGR on account of increasing demand from the population suffering from chronic diseases. The rapidly growing instances of chronic diseases and their treatment is driving the growth of the global curative therapeutics market.

Extended research and innovative procedural launches of the technological advanced devices and equipment for the early diagnosis and effective therapeutic treatment also supports the growth of the global curative therapeutics market in the next five years. Government policies and strict regulations toward utilization of curative therapies since they are new and protocolled clinical trials are further aiding the growth of the global curative therapeutics market.

Gene therapy, biotechnological advances, and pharmaceutical innovations to cure diseases through aggressive treatment are substantiating the growth of the global curative therapeutics market in the forecast years. The recent outbreak of COVID-19 pandemic is also expected to play a vital role in the growth of the global curative therapeutics market in the forecast period, until 2026.

Multiple market players and research institutes expanded their production capabilities for vector production. For example, Tevogen Bio collaborated with BioCentriq to produce Tevogen’s investigational COVID-19 T-Cell Therapy which is under review for Food and Drug Administration (FDA) approval.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Curative therapeutics Market"

https://www.techsciresearch.com/report/curative-therapeutics-market/8012.html

The global curative therapeutics market is segmented on the basis of type, indication, end user, competitional landscape, and regional distribution. Based on type, the market is further fragmented into biology modifying drugs, gene therapies, and cell therapies. Cell therapies are anticipated to hold the largest revenue shares of the market and support the futuristic market growth on the account of their increasing demand. Cell therapies are actively involved in the cure for cancer.

The ongoing clinical trials and increasing pharmaceutical and healthcare product development based on cell therapy is increasing and thus supporting the growth of the sub segment as well as the growth of the global curative therapeutics market in the upcoming five years. Gene therapy is also anticipated to register significant growth in the next five years on account of increasing research and technological advancements.

Surging demand for the precision medicine, and genomic medicine is further aiding the growth of the gene therapy and thus drive the growth of the global curative therapeutics market in the future five years. Biology modifying drugs are expected to register fastest growing CAGR in the future on account of increasing research on pharmaceutical products. Although the procedure is quite risky, the adaptation and FDA approvals are expected to support the future growth of the segment and the global curative therapeutics market in the forecast period.

Based on indication, the market is segmented into cancer, musculoskeletal disorders, neurodegenerative diseases, rare diseases, hepatitis C, and others. Cancer in anticipated to register fastest growing CAGR due to rapidly increasing number of cases on a global scale. Moreover, hepatitis C cases are also multiplying and thus demand for the curative therapeutics has surged in the recent past years.

Neurodegenerative diseases are expected to register significant growth in the revenue shares in the future five years due to increasing research on neural disorders, related diseases, and brain diseases such as Alzheimer’s, Wilson’s.

Pfizer, Inc., GlaxoSmithKline plc., Sanofi S.A. (Genzyme-Voyager Therapeutics), bluebird bio, Inc., Novartis International AG, Spark Therapeutics, Inc., Kite Pharma Inc., Gilead Sciences, Inc., are among the major market players leading the growth of the global curative therapeutics market.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8012

Customers can also request for 10% free customization on this report.

“North America is anticipated to dominate the global market, which can be attributed to the rising financial and physical investment in the research and technological advancement. Advanced product launches and advancement in the therapies for the betterment of the population by the multiple market players is further driving the growth of the global curative therapeutics market in the upcoming five years. Government bodies like FDA for the approval of the therapies and pharmaceutical products along with the participation of the private organizations in clinical trials is further aiding the growth of the global curative therapeutics market. Ongoing alliances, and acquisitions in the US contributes towards futuristic market growth. New market players may focus on studying the consumer demand and extended research along with the smart product launches to aid brand establishment,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Curative Therapeutics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2016-2026 Segmented By Type (Biology Modifying Drugs, Gene Therapies, Cell Therapies), By Indication (Cancer, Musculoskeletal Disorders, Neurodegenerative Diseases, Rare Diseases, Hepatitis C, Others), By End User (Pharmaceutical Companies, Academic & Research Institutions, Others), By Region”, has evaluated the future growth potential of global curative therapeutics market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global curative therapeutics market.

Browse Related Reports:

Global Cell & Gene Therapy Drug Delivery Devices Market By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) By Method (In Vitro v/s Ex Vivo) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/cell-and-gene-therapy-drug-delivery-devices-market/7364.html

Global Regenerative Medicine Market By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Others), By Application (Musculoskeletal Disorders, Wound Care, Others), By Material (Synthetic Material, Biologically Derived Material, Others), By Cell (Autologous, Allogenic), By Product (Biologic, Cell -based Medical Devices, Others), By Technique (Microfracture, Mosaicplasty), By Distribution Channel (Hospitals, Clinics, Others), By Region & Opportunities, 2025

https://www.techsciresearch.com/report/regenerative-medicine-market/4685.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[fmarkets]

Tevogen'Bio'Holdings'Inc'Faces'Decline'in'Company'Performance'Leading'into'First'Quarter'of'''''''' $TVGN #Stockmarket #Nasdaq

Company Behavior and Financial Results Show Troubling Trends for Tevogen Bio Holdings IncThe stock market has been buzzing with excitement as industry observers begin analyzing the first quarter performance of the Biotechnology and Pharmaceuticals industry in 2024. One company that has captured the attention of investors is Tevogen Bio Holding Inc. (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech firm that focuses on developing off-the-shelf, genetically unmodified T cell therapeutics in the fields